atorvastatin has been researched along with Diabetic Retinopathy in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camsari, UM; Ekerbicer, N; Gurpinar, T; Guvendi, G; Sisman, AR; Uysal, N | 1 |
| Bento, CF; Fernandes, R; Matafome, P; Pereira, P; Seiça, RM; Sena, CM | 1 |
| Bi, MC; Shi, H; Song, E; Song, XJ; Xu, CL; Xue, WX | 1 |
| Larijani, B; Mottaghi, S; Sharifi, AM | 1 |
| Bhansali, A; Gupta, A; Gupta, V; Thapar, S | 1 |
| Erkiliç, K; Koç, A; Mistik, S; Ozkiris, A | 1 |
3 trial(s) available for atorvastatin and Diabetic Retinopathy
| Article | Year |
|---|---|
Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema.
Topics: Administration, Oral; Atorvastatin; Chemotherapy, Adjuvant; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Exudates and Transudates; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Macular Edema; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides; Visual Acuity | 2004 |
Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy.
Topics: Atorvastatin; Blood Flow Velocity; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Eye; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Ophthalmic Artery; Pyrroles; Retinal Artery; Triglycerides | 2007 |
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Placebos; Pyrroles; Time Factors; Triglycerides | 2001 |
4 other study(ies) available for atorvastatin and Diabetic Retinopathy
| Article | Year |
|---|---|
Statins reduce testicular and ocular VEGF: A potential compromise to microcirculation.
Topics: Angiogenesis Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Down-Regulation; Eye; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microcirculation; Neovascularization, Pathologic; Rats, Wistar; Testis; Vascular Endothelial Growth Factor A | 2018 |
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet, Atherogenic; Heptanoic Acids; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrroles; Rats; Reactive Oxygen Species; Retina; Ubiquitin | 2014 |
Effect of atorvastatin on diabetic rat endothelial cells and retinal lesions.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Interleukin-4; Rats; Rats, Wistar; Tumor Necrosis Factor Ligand Superfamily Member 15; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
Atorvastatin: an efficient step forward in mesenchymal stem cell therapy of diabetic retinopathy.
Topics: Animals; Atorvastatin; Diabetic Retinopathy; Gene Expression Regulation; Genetic Therapy; Heptanoic Acids; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Receptors, CXCR4; Vascular Endothelial Growth Factor A | 2013 |